Engineered antibody fragments and the rise of single domains

Nature Biotechnology

Volumn 23, Issue 9, 2005, Pages 1126-1136

  Holliger, Philipp ^a   Hudson, Peter J ^b  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; BIOTECHNOLOGY; DRUG PRODUCTS; ENZYMES; TOXIC MATERIALS;

ANTIBODY FRAGMENTS; BIODISTRIBUTION; LIPOSOMES; TRIABODIES;

MONOCLONAL ANTIBODIES;

'BITE'; ABCIXIMAB; ARCITUMOMAB TC 99M; BITE MT103; CC 49; CDP 791; CERTOLIZUMAB PEGOL; CROFAB; DIGOXIN ANTIBODY F(AB) FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLIPOSOME; L 19; MDX H210; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 10H8; MONOCLONAL ANTIBODY C65KA; MONOCLONAL ANTIBODY L19; MONOCLONAL ANTIBODY R28M; NANOBODY; PEXELIZUMAB; RANIBIZUMAB; REAGENT; RECOMBINANT ANTIBODY; SGN 17; T 8466; TANDAB; THROMBOVIEW; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ANTIGEN BINDING; BIOSENSOR; BIOTECHNOLOGY; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CROHN DISEASE; DEEP VEIN THROMBOSIS; DIAGNOSTIC PROCEDURE; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG OVERDOSE; DRUG TARGETING; ECONOMIC ASPECT; ENVENOMATION; GENETIC TRANSCRIPTION; HUMAN; HYDROPHOBICITY; IMMUNOASSAY; IMMUNOGENICITY; IN VIVO STUDY; LYMPHOMA; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DOMAIN; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THROMBOSIS; VISCERAL METASTASIS;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BIOTECHNOLOGY; CLINICAL TRIALS; DRUG INDUSTRY; IMMUNOASSAY; IMMUNOGLOBULIN FRAGMENTS; INTERNET; MICE; MICE, NUDE; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; PROTEOMICS; TIME FACTORS;

EID: 27144432842     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1142     Document Type: Review

References (127)

1. Better, M., Chang, C.P., Robinson, R.R. & Horwitz, A.H. Escherichia coli secretion of an active chimeric antibody fragment. Science 240, 1041-1043 (1988).
2. Huston, J.S. et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85, 5879-5883 (1988).
3. Bird, R.E. et al. Single-chain antigen-binding proteins. Science 242, 423-426 (1988).
4. Holliger, P., Prospero, T. & Winter, G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90, 6444-6448 (1993).
5. Pei, X.Y., Holliger, P., Murzin, A.G. & Williams, R.L. The 2.0-A resolution crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a rearrangement of VH CDR3. Proc. Natl. Acad. Sci. USA 94, 9637-9642 (1997).
6. Iliades, P., Kortt, A.A. & Hudson, P.J. Triabodies: single chain Fv fragments without a linker form trivalent trimers. FEBS Lett. 409, 437-441 (1997).
7. Ward, E.S., Gussow, D., Griffiths, A.D., Jones, P.T. & Winter, G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341, 544-546 (1989).
8. Hudson, P.J. & Souriau, C. Engineered antibodies. Nat. Med. 9, 129-134 (2003).
9. Woof, J.M. & Burton, D.R. Human antibody-Fc receptor interactions illuminated by crystal structures. Nat. Rev. Immunol. 4, 89-99 (2004).
10. Ward, E.S. et al. From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol. Biol. Cell 16, 2028-2038 (2005).
11. Cardoso, R. M. et al. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22, 163-173 (2005).
12. Zhang, M.Y. et al. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J. Virol. 78, 9233-9242 (2004).
13. Adams, E.J., Chien, Y.H. & Garcia, K.C. Structure of a gammadelta T cell receptor in complex with the nonclassical MHC T22. Science 308, 227-231 (2005).
14. De Genst, E. et al. Strong in vivo maturation compensates for structurally restricted H3 loops in antibody repertoires. J. Biol. Chem. 280, 14114-14121 (2005).
15. De Genst, E. et al. Chemical basis for the affinity maturation of a camel single domain antibody. J. Biol. Chem. 279, 53593-53601 (2004).
16. Dooley, H. & Flajnik, M.F. Shark immunity bites back: affinity maturation and memory response in the nurse shark, Ginglymostoma cirratum. Eur. J. Immunol. 35, 936-945 (2005).
17. Streltsov, V. & Nuttall, S. Do sharks have a new antibody lineage? Immunol. Lett. 97, 159-160 (2005).
18. Streltsov, V.A. et al. Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc. Natl. Acad. Sci. USA 101, 12444-12449 (2004).
19. Stanfield, R.L., Dooley, H., Flajnik, M.F. & Wilson, I.A. Crystal structure of a shark single-domain antibody V region in complex with lysozyme. Science 305, 1770-1773 (2004).
20. Nuttall, S.D. et al. Selection and affinity maturation of IgNAR variable domains targeting Plasmodium falciparum AMA1. Proteins 55, 187-197 (2004).
21. Conrath, K. et al. Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J. Mol. Biol. 350, 112-125 (2005).
22. Saerens, D. et al. Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J. Biol. Chem. 279, 51965-51972 (2004).
23. Pleschberger, M. et al. An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology. Bioconjug. Chem. 15, 664-671 (2004).
24. Stijlemans, B. et al. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J. Biol. Chem. 279, 1256-1261 (2004).
25. Cortez-Retamozo, V. et al. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 64, 2853-2857 (2004).
26. Dottorini, T., Vaughan, C.K., Walsh, M.A., LoSurdo, P. & Sollazzo, M. Crystal structure of a human VH: requirements for maintaining a monomeric fragment. Biochemistry 43, 622-628 (2004).
27. Colby, D.W. et al. Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J. Mol. Biol. 342, 901-912 (2004).
28. Jespers, L., Schon, O., James, L.C., Veprintsev, D. & Winter, G. Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold. J. Mol. Biol. 337, 893-903 (2004).
29. Jespers, L., Schon, O., Famm, K. & Winter, G. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat. Biotechnol. 22, 1161-1165 (2004).
30. Souriau, C., Chiche, L., Irving, R. & Hudson, P. New binding specificities derived from Min-23, a small cystine-stabilized peptidic scaffold. Biochemistry 44, 7143-7155 (2005).
31. Binz, H.K. & Pluckthun, A. Engineered proteins as specific binding reagents. Curr. Opin. Biotechnol. 16, 459-469 (2005).
32. Midelfort, K.S. et al. Substantial energetic improvement with minimal structural perturbation in a high affinity mutant antibody. J. Mol. Biol. 343, 685-701 (2004).
33. Moroncini, G. et al. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. Proc. Natl. Acad. Sci. USA 101, 10404-10409 (2004).
34. James, L.C., Roversi, P. & Tawfik, D.S. Antibody multispecificity mediated by conformational diversity. Science 299, 1362-1367 (2003).
35. Linsley, P.S. New look at an old costimulator. Nat. Immunol. 6, 231-232 (2005).
36. Teeling, J.L. et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104, 1793-1800 (2004).
37. Casey, J.L. et al. Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical phase I/II study. Br. J. Cancer 86, 1401-1410 (2002).
38. Weir, A.N. et al. Formatting antibody fragments to mediate specific therapeutic functions. Biochem. Soc. Trans. 30, 512-516 (2002).
39. Dolezal, O. et al. Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the V(L) domain of the scFv-O (V(L)-V(H)) molecule is primarily responsible for formation of a tetramer-trimer equilibrium. Protein Eng. 16, 47-56 (2003).
40. Power, B.E., Kortt, A.A. & Hudson, P.J. Generation of recombinant multimeric antibody fragments for tumor diagnosis and therapy. Methods Mol. Biol. 207, 335-350 (2003).
41. Arndt, M.A., Krauss, J. & Rybak, S.M. Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers. FEBS Lett. 578, 257-261 (2004).
42. Griffiths, G.L. et al. Reagents and methods for PET using bispecific antibody pretargeting and 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J. Nucl. Med. 45, 30-39 (2004).
43. Olafsen, T. et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng. Des. Sel. 17, 21-27 (2004).
44. Wittel, U.A. et al. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl. Med. Biol. 32, 157-164 (2005).
45. Le Gall, F., Reusch, U., Little, M. & Kipriyanov, S.M. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng. Des. Sel. 17, 357-366 (2004).
46. Rosenthal, P.B., Waddington, L.J. & Hudson, P.J. Structure of an influenza neuraminidase-diabody complex by electron cryomicroscopy and image analysis. J. Mol. Biol. 334, 721-731 (2003).
47. Carmichael, J.A. et al. The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: implications for diabody flexibility. J. Mol. Biol. 326, 341-351 (2003).
48. Kenanova, V. et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 65, 622-631 (2005).
49. Robinson, M.K. et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res. 65, 1471-1478 (2005).
50. Sundaresan, G. et al. 1241-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J. Nucl. Med. 44, 1962-1969 (2003).
51. Jain, R.K. & Baxter, L.T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48, 7022-7032 (1988).
52. Rao, B.M., Lauffenburger, D.A. & Wittrup, K.D. Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nat. Biotechnol. 23, 191-194 (2005).
53. Oh, P. et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429, 629-635 (2004).
54. Adams, G.P. et al. A single treatment of yttrium-90-labeled CHX-A″-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res. 64, 6200-6206 (2004).
55. Matter, C.M. et al. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ. Res. 95, 1225-1233 (2004).
56. Brack, S.S., Dinkelborg, L.M. & Neri, D. Molecular targeting of angiogenesis for imaging and therapy. Eur. J. Nucl. Med. Mol. Imaging 31, 1327-1341 (2004).
57. Olafsen, T. et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng. Des. Sel. 17, 315-323 (2004).
58. Nielsen, U.B., Adams, G.P., Weiner, L.M. & Marks, J.D. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res. 60, 6434-6440 (2000).
59. Fujimori, K., Fisher, D.R. & Weinstein, J.N. Integrated microscopic-macroscopic pharmacology of monoclonal antibody radioconjugates: the radiation dose distribution. Cancer Res. 51, 4821-4827 (1991).
60. Knight, D.M. et al. Pharmacodynamic enhancement of the anti-platelet antibody fab abciximab by site-specific pegylation. Platelets 15, 409-418 (2004).
61. Huhalov, A. & Chester, K.A. Engineered single chain antibody fragments for radioimmunotherapy. Q. J. Nucl. Med. Mol. Imaging 48, 279-288 (2004).
62. Holliger, P., Wing, M., Pound, J.D., Bohlen, H. & Winter, G. Retargeting serum immunoglobulin with bispecific diabodies. Nat. Biotechnol. 15, 632-636 (1997).
63. Medzihradszky, K.F. et al. Glycoforms obtained by expression in Pichia pastoris improve cancer targeting potential of a recombinant antibody-enzyme fusion protein. Glycobiology 14, 27-37 (2004).
64. Sanz, L., Blanco, B. & Alvarez-Vallina, L. Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol. 25, 85-91 (2004).
65. Afanasieva, T.A. et al. Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy. Gene Ther. 10, 1850-1859 (2003).
66. Blanco, B., Holliger, P., Vile, R.G. & Alvarez-Vallina, L. Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted from gene-modified bystander cells. J. Immunol. 171, 1070-1077 (2003).
67. Lobato, M.N. & Rabbitts, T.H. Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules. Curr. Mol. Med. 4, 519-528 (2004).
68. Tanaka, T., Chung, G.T., Forster, A., Lobato, M.N. & Rabbitts, T.H. De novo production of diverse intracellular antibody libraries. Nucleic Acids Res. 31, e23 (2003).
69. Colby, D.W. et al. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. USA 101, 17616-17621 (2004).
70. Jendreyko, N. et al. Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J. Biol. Chem. 278, 47812-47819 (2003).
71. Zhao, Y., Brown, T.L., Kohler, H. & Muller, S. MTS-conjugated- antiactive caspase 3 antibodies inhibit actinomycin D-induced apoptosis. Apoptosis 8, 631-637 (2003).
72. Weisbart, R.H. et al. Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells. Cancer Lett. 195, 211-219 (2003).
73. Carter, P. Bispecific human IgG by design. J. Immunol. Methods 248, 7-15 (2001).
74. Xie, Z., Guo, N., Yu, M., Hu, M. & Shen, B. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J. Immunol. Methods 296, 95-101 (2005).
75. Zhu, Z., Presta, L.G., Zapata, G. & Carter, P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci. 6, 781-788 (1997).
76. Schlereth, B. et al. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain EpCAM-/CD3-bispecific antibody construct. Cancer Res. 65, 2882-2889 (2005).
77. Hoffmann, P. et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer 115, 98-104 (2005).
78. Kipriyanov, S.M. & Le Gall, F. Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr. Opin. Drug Discov. Devel. 7, 233-242 (2004).
79. Schlenzka, J. et al. Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma. Anticancer Drugs 15, 915-919 (2004).
80. Haas, C., Lulei, M., Fournier, P., Arnold, A. & Schirrmacher, V. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine. Vaccine 23, 2439-2453 (2005).
81. Lu, D. et al. A fully human recombinant IgG-Iike bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J. Biol. Chem. 280, 19665-19672 (2005).
82. Jimenez, X. et al. A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol. Cancer Ther. 4, 427-434 (2005).
83. Korn, T., Nettelbeck, D.M., Volkel, T., Muller, R. & Kontermann, R.E. Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J. Gene Med. 6, 642-651 (2004).
84. Schnyder, A. & Huwyler, J. Drug transport to brain with targeted liposomes. NeuroRx 2, 99-107 (2005).
85. Biburger, M., Weth, R. & Wels, W.S. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2. J. Mol. Biol. 346, 1299-1311 (2005).
86. Sharkey, R.M. & Goldenberg, D.M. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46 (Suppl. 1), 115S-127S (2005).
87. Zhang, M. et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood 100, 208-216 (2002).
88. Nakamura, T. et al. Antibody-targeted cell fusion. Nat. Biotechnol. 22, 331-336 (2004).
89. Nakamura, T. et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 23, 209-214 (2005).
90. Bang, S., Nagata, S., Onda, M., Kreitman, R.J. & Pastan, I. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin. Cancer Res. 11, 1545-1550 (2005).
91. Vallera, D.A. et al. Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice. Leuk. Res. 29, 331-341 (2005).
92. Krauss, J., Arndt, M.A., Vu, B.K., Newton, D.L. & Rybak, S.M. Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzymedouble dagger. Br. J. Haematol. 128, 602-609 (2005).
93. Halin, C. et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. 20, 264-269 (2002).
94. Smallshaw, J.E. et al. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat. Biotechnol. 21, 387-391 (2003).
95. Forsberg, G. et al. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br. J. Cancer 85, 129-136 (2001).
96. Enever, C., Tomlinson, I.M., Lund, J., Levens, M. & Holliger, P. Engineering high affinity superantigens by phage display. J. Mol. Biol. 347, 107-120 (2005).
97. Brignole, C. et al. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J. Natl. Cancer Inst. 96, 1171-1180 (2004).
98. van Broekhoven, C.L., Parish, C.R., Demangel, C., Britton, W.J. & Altin, J.G. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 64, 4357-4365 (2004).
99. Lu, M., Isogawa, M., Xu, Y. & Hilken, G. Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks. J. Virol. 79, 6368-6376 (2005).
100. Sharma, S. K. et al. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin. Cancer Res. 11, 814-825 (2005).
101. Mayer, A. et al. Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br. J. Cancer 90, 2402-2410 (2004).
102. Mosquera, L.A. et al. In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein. J. Immunol. 174, 4381-4388 (2005).
103. Michalet, X. et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307, 538-544 (2005).
104. Evans, E.J. et al. Crystal structure of a soluble CD28-Fab complex. Nat. Immunol. 6, 271-279 (2005).
105. Ravn, P. et al. Multivalent scFv display of phagemid repertoires for the selection of carbohydrate-specific antibodies and its application to the Thomsen-Friedenreich antigen. J. Mol. Biol. 343, 985-996 (2004).
106. Jespers, L., Bonnert, T.P. & Winter, G. Selection of optical biosensors from chemisynthetic antibody libraries. Protein Eng. Des. Sel. 17, 709-713 (2004).
107. Sepp, A., Tawfik, D.S. & Griffiths, A.D. Microbead display by in vitro compartmentalisation: selection for binding using flow cytometry. FEBS Lett. 532, 455-458 (2002).
108. de Wildt, R.M., Tomlinson, I.M., Ong, J.L. & Holliger, P. Isolation of receptor-ligand pairs by capture of long-lived multivalent interaction complexes. Proc. Natl. Acad. Sci. USA 99, 8530-8535 (2002).
109. Dolk, E. et al. Induced refolding of a temperature denatured Ilama heavy-chain antibody fragment by its antigen. Proteins 59, 555-564 (2005).
110. Dolk, E. et al. Isolation of Ilama antibody fragments for prevention of dandruff by phage display in shampoo. Appl. Environ. Microbiol. 71, 442-450 (2005).
111. Nuttall, S.D. et al. Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70. Eur. J. Biochem. 270, 3543-3554 (2003).
112. Tanaka, T., Lobato, M.N. & Rabbitts, T.H. Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. J. Mol. Biol. 331, 1109-1120 (2003).
113. Wunderlich, M., Martin, A. & Schmid, F.X. Stabilization of the cold shock protein CspB from Bacillus subtilis by evolutionary optimization of Coulombic interactions. J. Mol. Biol. 347, 1063-1076 (2005).
114. Dill, K. et al. Immunoassays based on electrochemical detection using microelectrode arrays. Biosens. Bioelectron. 20, 736-742 (2004).
115. Hamelinck, D. et al. Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol. Cell Proteomics 4, 773-784 (2005).
116. Orntoft, T.F. & Vestergaard, E.M. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 20, 362-371 (1999).
117. Prescher, J.A., Dube, D.H. & Bertozzi, C.R. Chemical remodelling of cell surfaces in living animals. Nature 430, 873-877 (2004).
118. Chambers, R.S. High-throughput antibody production. Curr. Opin. Chem. Biol. 9, 46-50 (2005).
119. Grosse-Hovest, L. et al. Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int. J. Cancer; published online 7 July 2005. http://www3.interscience.wiley.com/cgi-bin/abstract/ 110559371/ABSTRACT
120. Holliger, P. et al. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3xanti-CEA bispecific diabodies and B7xantiCEA bspecific fusion proteins. Cancer Res. 59, 2909-2916 (1999).
121. Pattersen, E.F. et al. UCFS Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004)
122. Olafsen, T. et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res. 65, 5907-5916 (2005).
123. Shen, S. et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J. Nucl. Med. 46, 642-651 (2005).
124. Nellis, D.F. et al. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol. Prog. 21, 221-232 (2005).
125. Ebbinghaus, C. et al. Engineered vascular-targeting antibody-interferon- gamma fusion protein for cancer therapy. Int. J. Cancer 116, 304-313 (2005).
126. Wong, J.Y. et al. Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anti-carcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin. Cancer Res. 10, 5014-5021 (2004).
127. Hulstein, J.J. et al. A novel nanobody that detects the gain-of-function phenotype of Von Willebrand factor in adamts13 deficiency and Von Willebrand disease type 2B. Blood; published online 12 July 2005. http://www.bloodjournal. org/cgi/reprint/2005-03-1153v1